CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Benitec Biopharma Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Benitec Biopharma Ltd
Benitec Biopharma, L 14 114 William St
Phone: +61 386927222p:+61 386927222 MELBOURNE, VIC  3000  Australia Ticker: BLTBLT

Business Summary
Benitec Biopharma Limited is a biotechnology company. The Company is engaged in progressing programs through the clinic; the commercialization of its Intellectual Property (IP); development of its therapeutic pipeline and pre-clinical programs, and funding, and protecting and building the IP estate. Its In-house product candidates include TT-034, BB-HB-331, BB-AMD-211 and ddRNAi therapeutic. It is focused on commercialization by licensing and partnering of patents and licenses in biotechnology, in functional genomics, with applications in biomedical research and human therapeutics. It has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, deoxyribonucleic acid (DNA)-directed ribonucleic acid interference (ddRNAi). The Company is engaged in developing treatments for chronic human conditions, such as hepatitis B, wet age-related macular degeneration (AMD), and oculopharyngeal muscular dystrophy (OPMD) based on this technology.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
IRA CQ
Score
Moody's
Rating
Fitch
Rating
DBRS
Rating
Morningstar
Rating
YesYes-------

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/20196/30/2019YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Executive Chairman of the Board Jerel A.Banks 6/14/2018 10/26/2016
Chief Executive Officer, Company Secretary GregoryWest 8/10/2016 5/26/2011
Chief Financial Officer BryanDulhunty 7/1/2016 7/1/2016
5 additional Officers and Directors records available in full report.

Business Names
Business Name
Benitec Ltd
Benitec Ltd.
BLT
4 additional Business Names available in full report.

General Information
Number of Employees: 13 (As of 6/30/2014)
Outstanding Shares: 257,029,426 (As of 6/30/2019)
Shareholders: 3,571
Stock Exchange: ASX
Fax Number: +61 399669923


Copyright © 2019 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, November 18, 2019